Cefpodoxime Proxetil + Ambroxol HCl Tablets Manufacturer in India

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Genliva Wellness LLP develops Cefpodoxime Proxetil + Ambroxol HCl Tablets for respiratory bacterial infections accompanied by thick mucus accumulation and airway congestion. The formulation is commonly prescribed in bronchitis, lower respiratory tract infections, throat infections, productive cough conditions, and bacterial chest congestion requiring combined antibacterial and mucolytic therapy.

Cefpodoxime Proxetil belongs to the third-generation cephalosporin antibiotic class and acts against susceptible respiratory bacterial pathogens, while Ambroxol HCl reduces mucus viscosity and improves bronchial secretion clearance. This dual combination is frequently preferred in respiratory care protocols where bacterial infection and mucus obstruction occur simultaneously.

As a trusted Cefpodoxime Ambroxol Tablets Manufacturer in India, Genliva Wellness LLP manufactures respiratory antibacterial formulations for pharmaceutical distributors, respiratory care product suppliers, and international medicine export markets.

Cefpodoxime Proxetil + Ambroxol HCl Tablets are formulated for respiratory antibacterial and mucus clearance therapy.

Third-generation cephalosporin and mucolytic combination
Frequently prescribed in bronchial bacterial conditions
Reduces thick mucus accumulation in airways
Optimized oral respiratory care formulation
Manufactured using premium pharmaceutical ingredients
Intended for respiratory infection treatment protocols

This formulation is administered in respiratory bacterial and productive cough treatment therapies.

Treatment of bronchitis and chest infections
Management of productive cough conditions
Prescribed in throat and airway bacterial infections
Administered in respiratory mucus congestion
Utilized in lower respiratory tract infection care
Frequently selected in outpatient respiratory therapies

Cefpodoxime Proxetil + Ambroxol HCl Tablets combine antibacterial and mucolytic action for respiratory care.

Clears mucus congestion from respiratory passages
Valuable in bronchial bacterial infection management
Improves airway secretion drainage
Combines respiratory antibacterial and mucolytic therapy
Frequently preferred in productive cough treatment
Maintains extended respiratory antibacterial coverage